Patients at the Heart of the Scientific Dialogue: An Industry Perspective by Dany Habr, Brittany Wolf Gianares, Kristine W. Schuler, Dheepa Chari

Get full text

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence by Erica Chilson, Daniel A. Scott, Beate Schmoele-Thoma, Wendy Watson, Mary M. Moran, Raul Isturiz

Get full text

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age by Kai Chu, Yuemei Hu, Hongxing Pan, Jingliang Wu, Dandan Zhu, Mariano M. Young, Li Luo, Zhuobiao Yi, Peter C. Giardina, William C. Gruber, Daniel A. Scott, Wendy Watson

Get full text

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis by Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch

Get full text

P579: A PHASE 4 STUDY OF FRACTIONATED GEMTUZUMAB OZOGAMICIN ON QT INTERVAL AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA by P. Montesinos, V. Kota, J. Brandwein, P. Bousset, R. J. Benner, E. Vandendries, M. F. McMullin

Get full text

P376: VENO-OCCLUSIVE DISEASE RISK AND OTHER OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC... by Marcos de Lima, Partow Kebriaei, Francesco Lanza, Christina Cho, Gizelle Popradi, Manmeet Kaur, Mei-Jie Zhang, Fan Zhang, Saara Tikka, Erik Vandendries, Kofi Asomaning, Stephanie Dorman, Matthias Stelljes, David Marks, Wael Saber

Get full text

Real-world impact and effectiveness of MenACWY-TT by Rodolfo Villena, Paula Kriz, Myint Tin Tin Htar, Cindy Burman, Jamie Findlow, Paul Balmer, Luis Jodar

Get full text

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations by Erik Hahn, Renae Chavira, Lance Wollenberg, Weiwei Tan, Micaela B. Reddy

Get full text

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico by Matthew Wasserman, Maria Gabriela Palacios, Ana Gabriela Grajales, F. Berenice Baez/Revueltas, Michele Wilson, Cheryl McDade, Raymond Farkouh

Get full text

Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured c... by Jinma Ren, Paul Cislo, Joseph C. Cappelleri, Patrick Hlavacek, Marco DiBonaventura

Get full text

Estimated global public health and economic impact of COVID-19 vaccines in the pre-omicron era using real-world empirical data by Jingyan Yang, Shailja Vaghela, Benjamin Yarnoff, Solene De Boisvilliers, Manuela Di Fusco, Timothy Lee Wiemken, Moe H. Kyaw, John M. McLaughlin, Jennifer L. Nguyen

Get full text

Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclon... by Ellen Q. Wang, Nitin Kaila, David Plowchalk, Leonid Gibiansky, Carla Yunis, Kevin Sweeney

Get full text

Reduction of therapeutic antibody self-association using yeast-display selections and machine learning by Emily K. Makowski, Hongwei Chen, Matthew Lambert, Eric M. Bennett, Nicole S. Eschmann, Yulei Zhang, Jennifer M. Zupancic, Alec A. Desai, Matthew D. Smith, Wenjia Lou, Amendra Fernando, Timothy Tully, Christopher J. Gallo, Laura Lin, Peter M. Tessier

Get full text

After 25 years of drug development, do we know JAK? by David A Martin, Mahta Mortezavi

Get full text

Substantial health and economic burden of COVID-19 during the year after acute illness among US adults not at high risk of severe COVID-19 by Amie Scott, Wajeeha Ansari, Richard Chambers, Maya Reimbaeva, Tomasz Mikolajczyk, Michael Benigno, Florin Draica, Joanna Atkinson

Get full text

Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials by Gustavo Citera, Rakesh Jain, Fedra Irazoque, Hugo Madariaga, David Gruben, Lisy Wang, Lori Stockert, Karina Santana, Abbas Ebrahim, Dario Ponce de Leon

Get full text

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer by Kamrine E. Poels, Adam J. Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O. McDonald, Weiwei Tan, Aaron Hata, Scott L. Weinrich, Helena A. Yu, Franziska Michor

Get full text

Vehicles for atopic dermatitis therapies: more than just a placebo by Simon G. Danby, Zoe D. Draelos, Linda F. Stein Gold, Amy Cha, Bonnie Vlahos, Laraine Aikman, Paul Sanders, Dan Wu-Linhares, Michael J. Cork

Get full text

P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A by Katja Weisel, Nizar J Bahlis, Paula Rodríguez-Otero, Andrea Viqueira, Shen-Wu Wang, Sangeetha Sathiah, Douglas Robinson, Thomas O’brien, Hang Quach

Get full text

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A by Paula Rodríguez-Otero, Hang Quach, Katja Weisel, Andrea Viqueira, Shen-Wu Wang, Phineas T. Hamilton, Tao Xie, Thomas O’brien, Nizar J Bahlis

Get full text